Overview

Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer

Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This is an exploratory interventional study that initiates chemotherapy with letrozole in patients with estrogen receptor positive/HER2-negative breast cancer preoperably.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Center, Korea
Treatments:
Cyclophosphamide
Docetaxel
Doxorubicin
Estrogens
Letrozole
Leuprolide
Liposomal doxorubicin